Framing expectations in early HIV cure research

Trends in Microbiology

Volumn 22, Issue 10, 2014, Pages 547-549

  Dubé, Karine ^a   Henderson, Gail E ^a   Margolis, David M ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Expectations; Experiments; HIV cure research; Trials

Indexed keywords

HISTONE DEACETYLASE INHIBITOR; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; OKT 3; RECOMBINANT INTERLEUKIN 2; VORINOSTAT; ZIDOVUDINE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CD4+ T LYMPHOCYTE; CLINICAL EXPERIMENT; COMBINATION CHEMOTHERAPY; DRUG EFFICACY; DRUG SAFETY; EXPECTATION; EXPERIMENT; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS 1 INFECTION; HUMAN IMMUNODEFICIENCY VIRUS CURE RESEARCH; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LATENT VIRUS INFECTION; MEDICAL RESEARCH; MEDICAL TERMINOLOGY; NOTE; PATIENT MONITORING; REMISSION; RISK BENEFIT ANALYSIS; T LYMPHOCYTE ACTIVATION; TRANSLATIONAL RESEARCH; TREATMENT OUTCOME; VIRAL CLEARANCE; VIRUS CARRIER; VIRUS LATENCY; HIV INFECTIONS; HUMAN IMMUNODEFICIENCY VIRUS 1; PHYSIOLOGY; VIROLOGY;

BIOMEDICAL RESEARCH; HIV INFECTIONS; HIV-1; HUMANS;

EID: 84908481348     PISSN: 0966842X     EISSN: 18784380     Source Type: Journal    
DOI: 10.1016/j.tim.2014.08.003     Document Type: Note

References (12)

1. Horwitz J.P., et al. Nucleosides. V. The monomesylates of 1-(2'-deoxy-beta-Dlyxofuranosyl)thymidine. J. Org. Chem. 1964, 29:2076-2078.
2. Advisory Committee on Human Radiation Experiments Final Report 1995, US Government Printing Office.
3. Prins J.M., et al. Immuno-activation with anti-CD3 and recombinant human IL-2 in HIV-1 infected patients on potent antiretroviral therapy. AIDS 1999, 13:2405-2410.
4. + count-guided interruption of antiretroviral treatment. N. Engl. J. Med. 2006, 355:2283-2296.
5. Allers K., et al. Evidence for the cure of HIV infection by CCR5δ32/δ32 stem cell transplantation. Blood 2011, 117:2791-2799.
6. Persaud D., et al. Absence of detectable HIV-1 viremia after treatment cessation in an infant. N. Engl. J. Med. 2013, 369:1828-1835.
7. Lehrman G., et al. Depletion of latent HIV-1 infection in vivo: a proof-of-concept study. Lancet 2005, 366:549-555.
8. Archin N.M., et al. Expression of latent HIV induced by the potent HDAC inhibitor suberoylanilide hydroxamic acid. AIDS Res. Hum. Retroviruses 2009, 25:207-212.
9. + T cells after multiple doses of vorinostat. J. Infect. Dis. 2014, 10.1093/infdis/jiu155.
10. Saglio F., et al. The time is now: moving toward virus-specific T cells after allogeneic hematopoietic stem cell transplantation as the standard of care. Cytotherapy 2014, 16:149-159.
11. Appelbaum P.S., et al. The therapeutic misconception: informed consent in psychiatric research. Int. J. Law Psychiatry 1982, 5:319-329.
12. Henderson G.E., et al. Clinical trials and medical care: defining the therapeutic misconception. PLoS Med. 2007, 4:1735-1738.